In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selective Genetics Inc.

www.selectivegenetics.com

Latest From Selective Genetics Inc.

Spinal Concepts: Leading Abbott into the Spine Market

The success of Abbott Laboratories' acquisition of Spinal Concepts may depend as much on company restraint as on company resources.
Medical Device Strategy

Quorex Pharmaceuticals Inc.

Quorex Pharmaceuticals has discovered a regulatory molecule and signaling pathway that permits bacterial cells to sense when they have achieved the population density (a quorum) needed to initiate the successful infection of a host. It is developing compounds that disrupt that communication system, which is found in a range of pathogens, to prevent infection.
BioPharmaceutical

The Device Angle on Angiogenesis

Ten years ago, researchers observed that injecting vascular endothelial growth factors or fibroblast frowth factors into animal models of ischemia stimulated the formation of new blood vessels. The discovery that, with a bit of prompting, the body's natural capacity for angiogenesis could be accelerated, has drawn more than a dozen drug firms and a handful of cardiovascular device companies into the search for a biological alternative that can aid or replace current cardiovascular interventions, or even delay the progression of heart disease.
BioPharmaceutical Medical Device

The Gene Therapy Superhighway

Gene Therapy companies need delivery devices for their therapies and device companies must increasingly embrace biotechnologies to improve and differentiate their increasingly commoditized offerings. In a handful of device/biotech deals signed in the pas year, device companies are gaining exclusive worldwide rights to new cardiovascular gene therapies. The next meeting ground for gene therapies and devices: orthobiologics.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Selective Genetics Inc.
  • Senior Management
  • Robert T Abbott, CEO
    Mark A McCutchen, VP, CFO
    Glenn Pierce, MD, PhD, VP, Preclinical R&D
  • Contact Info
  • Selective Genetics Inc.
    Phone: (619) 625-0100
    11035 Roselle St.
    San Diego, CA 92121
    USA
UsernamePublicRestriction

Register